Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics, FDNA Ink Deal to Integrate Technologies

NEW YORK (GenomeWeb) – Ambry Genetics announced today that it has signed an agreement to integrate its AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.

Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses, based on a database of more than 10,000 rare disease syndromes. AmbryPort 2.0 is a secure online portal for genetic test ordering, tracking, and results reporting.

According to Ambry, the integration will enable clinicians using Face2Gene to securely pass phenotypic information and insights from Face2Gene analysis to AmbryPort 2.0, and gain greater diagnostic insights from the molecular data.

Specific terms of the deal were not disclosed.

"Bringing FDNA's artificial intelligence and facial analysis technologies to Ambry Genetics is facilitating a new age in precision medicine," FDNA CEO Dekel Gelbman said in a statement. "We expect a dramatic increase in patients who find answers, increased understanding of rare diseases, and increased access for drug developers to create precision therapeutics for this large but underserved patient population."

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.